Hemangioma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 18, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Hemangioma. It connects disease background, epidemiology, a target-mechanism anchor, clinical competition, transaction activity, unmet need and market attractiveness for portfolio and business-development decisions.

Executive assessment

Hemangioma receives a directional strategic score of 59/100. The synthesis combines unmet need (74/100), competitive intensity (96/100, where a higher value means more competition) and market attractiveness (80/100). It is an evidence-organizing framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000)

The reproducible entity is Patsnap disease ID 8cc43ba32aa140d0959a7ee7e922e09c with MeSH identifier D006391. Entity-level identifiers matter because rare disorders often carry historical names, gene-defined subtypes and overlapping clinical labels. Strategy teams should lock the intended label and synonym set before comparing epidemiology, trials and deals.

A useful target product profile must specify the treatable phenotype, age and severity range, diagnostic confirmation, prior-therapy requirements, treatment setting, acceptable safety profile and endpoint. In Hemangioma, an overly broad label can inflate the theoretical market while diluting biological signal and making recruitment less predictable.

The care pathway should be mapped from symptom recognition through specialist referral, molecular or biochemical confirmation, treatment initiation and longitudinal monitoring. Diagnostic delay, fragmented referral and limited centers may be as important commercially as drug efficacy. These barriers should appear explicitly in launch and evidence-generation plans.

Epidemiology and disease burden

Epidemiology signal 1: Epidemiology of myasthenia gravis in France: Incidence, prevalence, and comorbidities based on national healthcare insurance claims data Epidemiology of myasthenia gravis in France:Incidence, prevalence, and comorbidities based onnational healthcare insurance claims data

Using EGB data, this study is the first to provide insight into the epidemiology of MG in France. These data highlight a much higher incidence and prevalence of the disease than generally reported, with a very high prevalence among men over 70. In addition, there is a clear statistical association between MG and certain comorbidities, notably the existence of diseases that affect the thymus, as well as an increased prevalence of cancer. Our results appear to modify the epidemiological know- ledge of MG, challenging previous studies conducted in Western countries, especially in Europe. In particular, we found an incidence of MG of over 50 per million person-years, far above the highest estimation in the literature of 30 per million person-years [7]. Focusing on the last years of the study period, the prevalence was above 500 per million people (reaching a peak of 586 patients per million people), whereas the literature suggests a range of 15 to 320 per million. These significant differences can be attributed to several factors, although they cannot be verified by our study. The methodo- logy employed in previous studies relied on retrospective analyses (study of medical records or hospital database analyses), which were probably not exhaustive. Studies using the EGB are undoubtedly much more effective for identifying patients with specific diseases, and the use of our algorithm likely enabled us to be almost exhaustive in the identification of MG patients. Furthermore, the EGB data we used are more recent (2008–2018) than most of the literature data and part of the increase in in

Review the underlying epidemiology source

Epidemiology signal 2: Incidence and prevalence of mucous membrane pemphigoid with ocular involvement: a retrospective analysis using the TriNetX database

The cumulative prevalence was 6.72 per 100,000 persons, and the cumulative incidence rate was 1.41 per 100,000 persons over the 11-year period. Incidence increased over time from 1.00/100,000 in 2013 to 2.06/100,000 in 2023 (Fig. 1) with a drop in 2020. With the exception of three slight decreases in the yearly incidence, the first in 2014 (1.00/100,000 in 2013 to .92/100,000 in 2014), the second in 2016 (1.50/100,000 in 2016 to 1.36/100,000 in 2018), and the third from 2019 into 2020 (1.53/100,000 in 2019 to 1.26/ 100,000), there was continuously increasing incidence and prevalence throughout the 11-year period to 10.3/100,000 in 2023 (Fig. 2). The cumulative incidence and prevalence for females was 1.58/100,000 and 7.83/100,000, respectfully, which was higher than that of males (1.18/100,000; 5.39/100,000). Individuals who were not of Hispanic or Latino origin had a cumulative incidence of 1.57/100,000 compared to 0.49/100,000 in those who were of Hispanic or Latino origin. A similar trend was seen among their cumulative prevalence as well, which was 8.81/ 100,000 versus 2.31/100,000. White patients had the highest incidence and prevalence throughout the 11-year period (1.64/ 100,000, 8.55/100,000). Native Hawaii and other Pacific Islanders had the lowest cumulative incidence at 0.42/100,000, while Black or African American patients had the lowest cumulative prevalence at 2.30/100,000 (Table 3). The overall incidence of patients under the age of 70 was 1.47/100,000 compared to 1.54/ 100,000 in patients aged 70 and older. Prevalence followed the same pattern with 7.46/100,

Review the underlying epidemiology source

Epidemiology signal 3: Demographics, Trends, and Cardiovascular Mortality in Kaposi Sarcoma Patients in the United States: An Analysis of Surveillance, Epidemiology, and End Results Database Demographics, Trends, and Cardiovascular Mortality inKaposi Sarcoma Patients in the United States: AnAnalysis of Surveillance, Epidemiology, and End ResultsDatabase

1. O. Radu and L. Pantanowitz, “Kaposi Sarcoma,” Archives of Pathology & Laboratory Medicine 137, no. 2 (February 2013): 289–294, https://doi. org/10.5858/arpa.2012-0101-RS. 2. E. Cesarman, B. Damania, S. E. Krown, J. Martin, M. Bower, and D. Whitby, “Kaposi Sarcoma,” Nature Reviews Disease Primers 5, no. 1 (January 2019): 9, https://doi-org.sutd.idm.oclc.org/10.1038/s41572-019-0060-9. 3. R. Vangipuram and S. K. Tyring, “Epidemiology of Kaposi Sarcoma: Review and Description of the Nonepidemic Variant,” International Journal of Dermatology 58, no. 5 (May 2019): 538–542, https://doi-org.sutd.idm.oclc.org/ 10.1111/ijd.14080. 4. E. A. Mesri, E. Cesarman, and C. Boshoff, “Kaposi's Sarcoma and Its Associated Herpesvirus,” Nature Reviews Cancer 10, no. 10 (October 2010): 707–719, https://doi-org.sutd.idm.oclc.org/10.1038/nrc2888. 5. S. Peprah, E. A. Engels, M. J. Horner, et al., “Kaposi Sarcoma Incidence, Burden, and Prevalence in United States People With HIV, 2000‐2015,” Cancer Epidemiology, Biomarkers & Prevention 30, no. 9 (September 2021): 1627–1633, https://doi-org.sutd.idm.oclc.org/10.1158/1055-9965.EPI-21-0008. 6. N. Iftode, M. A. Rădulescu, Ș. S. Aramă, and V. Aramă, “Update on Kaposi Sarcoma‐Associated Herpesvirus (KSHV or HHV8) ‐ Review,” Romanian Journal of Internal Medicine 58, no. 4 (December 2020): 199– 208, https://doi-org.sutd.idm.oclc.org/10.2478/rjim-2020-0017. 7. D. L. White, A. Oluyomi, K. Royse, et al., “Incidence of AIDS‐Related Kaposi Sarcoma in All 50 United States From 2000 to 2014,” JAIDS Journal of Acquired Immune Deficiency Syndromes 81, no. 4 (August 2019): 387–394, https://doi-org.sutd.idm.oclc.org/10.1097/QAI.0000000000002050. 8. A. W. Armstrong, K. H. L

Review the underlying epidemiology source

Epidemiology should be converted into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence are not interchangeable; estimates from different age bands, case definitions or health systems should not be pooled without adjustment.

For Hemangioma, the next population work should quantify diagnostic yield, severity distribution, referral-center concentration, treatment penetration and survival or progression. Sensitivity analyses should show how each assumption affects recruitment, peak penetration and budget impact. A transparent range is more useful than a single precise-looking estimate built from incompatible sources.

Unmet need and patient-value thesis

The unmet-need thesis must name the failure that a new intervention will change: irreversible progression, incomplete disease control, treatment-limiting toxicity, burdensome administration, weak durability, delayed diagnosis or lack of options for a biomarker-defined subgroup. High disease severity alone does not prove that a clinical program can demonstrate benefit.

A strong Hemangioma strategy connects mechanism to a pre-specified responder population and an endpoint understood by regulators, clinicians, patients and payers. It also tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Patient-reported outcomes, functional measures and health-resource use may add value when standard biomarkers do not capture daily burden.

The recommended first development population is the narrowest segment that remains operationally recruitable and has the clearest biological rationale. Expansion should follow evidence of target engagement and response rather than precede it. This sequencing protects capital and improves the interpretability of early clinical results.

Target mechanism anchor: PTH1R

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8397094). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:30975883, PubMed:35932760). PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:20172855, PubMed:30975883, PubMed:35932760). PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH (PubMed:35932760).

The mechanism anchor for this landscape is PTH1R. It is a pathway hypothesis, not an assertion that every patient is target-dependent. Translational diligence should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream pathway modulation and a therapeutic window in the intended population.

Critical experiments include orthogonal engagement assays, dose–response work in disease-relevant systems, biomarker qualification, evaluation of compensatory pathways and explicit on-target and off-target safety testing. Human evidence should receive more weight than model-only findings. Negative results in related mechanisms should be analyzed for exposure, population, endpoint and biological lessons.

A go decision requires a chain of evidence: target present in the relevant tissue; modulation achieved at tolerated exposure; pharmacodynamic change observed; and that change plausibly connected to clinical benefit. If any link is missing, the program should remain at a lower investment gate.

Clinical development and competition

The focused query returned 443 registered studies overall. Recent sampled records include:

• NCT07768085 — Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT; status Not yet recruiting; phase Not Applicable; sponsor ShengJing Hospital; enrollment 40000.
• ChiCTR2600128786 — Clinical Characteristics and Treatment Outcomes of Segmental Infantile Hemangiomas; status Not yet recruiting; phase Not Applicable; sponsor The Ninth People's Hospital of Shanghai Jiaotong University Medical College; enrollment 300.
• NCT07707661 — Application of Super-Resolution Ultrasound (SRUS) in Liver Tumor (SRUS); status Not yet recruiting; phase Not Applicable; sponsor Shanghai Eastern Hepatobiliary Surgery Hospital; enrollment 350.

Trial count is not equivalent to the number of competing products. Observational studies, natural-history cohorts and multiple trials from one asset can distort the headline. Each record should be normalized by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy must compare against the likely standard of care at launch, not only today's treatment. Potential whitespace may come from earlier intervention, genotype selection, improved durability, reduced monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim should be visible in protocol design and prospectively defined analyses.

Recruitment risk deserves its own workstream in Hemangioma. Site density, diagnostic testing, competing protocols, travel burden and screen-failure rates should inform country and center selection. Natural-history data can reduce uncertainty but should not substitute for a well-controlled efficacy strategy when endpoints are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This negative signal can mean limited partnering momentum, a broader deal label or asset-level transactions not indexed to the exact indication. Target- and asset-based comparable searches should be added before valuation.

Headline deal value is rarely a clean comparable. Upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope must be separated. A defensible comparable set matches indication, target, modality, stage and territory, then explains every remaining difference.

Partner readiness depends on a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that can retire a material portion of risk.

For Hemangioma, direct transaction scarcity can create whitespace, but it can also signal weak validation or a difficult commercial model. Broader pathway deals are useful only when their scientific and economic relevance is made explicit. Avoid treating unrelated rare-disease transactions as interchangeable simply because both populations are small.

Market attractiveness and access

Market attractiveness is shaped by diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, current alternatives, monitoring burden and geographic reimbursement. A rare population can still be attractive when identification is reliable, centers are concentrated and effect size is meaningful; a larger population can disappoint when diagnosis and access are fragmented.

The commercial model should include conservative, base and upside scenarios. Key variables are diagnosed prevalence, eligible share, launch timing, competing approvals, net price, persistence and achievable penetration. Each assumption should have a source, date and range. Scenario outputs should be updated when new epidemiology, trial or transaction evidence arrives.

Payer research should begin before pivotal design so comparator, endpoint and follow-up choices support reimbursement as well as approval. Evidence plans may need quality-of-life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The strongest value proposition ties clinical benefit to outcomes that matter across stakeholders.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate that PTH1R is relevant in the selected phenotype.
• Translation risk: connect engagement to a biomarker and clinically meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing capacity and screen-failure assumptions.
• Commercial risk: test access, pricing and adoption with clinicians and payers.
• Data risk: interpret zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are: confirm population and natural history; validate mechanism in human evidence; define a differentiated target product profile; establish early proof of mechanism; and scale only after clinical signal, operational feasibility and commercial logic converge. Every gate needs pre-agreed stop criteria.

Strategic recommendation

Hemangioma merits continued, milestone-based evaluation. The opportunity is strongest if a biomarker or phenotype can identify patients with coherent biology, if PTH1R modulation is measurable, and if the proposed benefit is meaningful against future care. The current evidence supports further diligence rather than an unconditional investment decision.

The near-term business-development objective is to build a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard provides a common language for comparison, while the attached evidence and explicit gaps preserve analytical traceability.

Methodology and source note

This report was assembled on August 18, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update. Counts are directional search outputs, not clinical, regulatory or investment advice.

Ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Before a transaction or portfolio commitment, rerun searches with synonyms, disease roll-ups, gene or pathway names and asset filters.

Conclusion

The central question for Hemangioma is whether a biologically grounded therapy can produce a material patient benefit in an identifiable population and remain differentiated through launch. The current evidence supplies a structured starting point; the gaps define the next diligence plan. Connected MCP searches make the thesis refreshable as disease knowledge, trials and transactions evolve.